Toggle menu

MAPP2 Study

Start date:
June 2018
End date:
June 2020
Co-ordinated by:
Rachel O'Brien
Main trial site:
Royal Infimary Edinburgh

The development of a new point of care test will detect miR-122 and allow point of care diagnosis of paracetamol toxicity with the aim of improved patient stratification on presentation to hospital and, therefore, improve patient care.

The aim of the study is to establish a biobank of human serum samples from patients with paracetamol overdose to develop and test the performance of our point of care test. This is a prospective, observational cohort study of participants aged 16 years or over presenting to the ED/AMU aiming to recruit 326 participants.

Chief Investigator

Dr James Dear

Consultant in Acute Medicine & Toxicology

Research Team

Rachel O'Brien

Lead Research Nurse

Caroline Blackstock

AMU Senior Research Nurse

Claire Cheyne

Research Nurse- Bank Staff

More EMERGE Trials

Evaluating the role of early CT Coronary Angiography on patients with suspected or confirmed Acute Coronary Syndrome.

Read more

RAPID-CTCA Trial

Evaluating the role of early CT Coronary Angiography

MAPP2 Study

The Markers and Paracetamol Poisoning Study 2

EHA - Epidemiological analysis for the Hereditary Angioedema Disease is an international, multicentre, epidemiological study that aims to explore the feasibility of a new Dried Blood Spot (DBS) filtercard-based screening algorithm and thereby the prevalence of the Hereditary Angioedema.

Read more

EHA Study

EHA - Epidemiological analysis for the Hereditary Angioedema Disease